혈관염 시장 : 현황 분석 및 예측(2023-2030년)

Vasculitis is a condition where blood vessels including veins, capillaries, and arteries undergo inflammation which causes them to thicken decreasing the diameter of blood vessels. Vasculitis is differentiated into various groups according to the size of the blood vessels they affect. Vasculitis can lead to certain adverse side effects like blockage of blood flow, which could cause organ damage. The vasculitis market is growing at a tremendous rate owing to an increased focus on early detection and prevention, rising research and development activities, a rise in incidences of chronic diseases, advances in treatment options, and a rise in the geriatric population. For instance, in November 2021, a clinical-stage biopharmaceutical company, InflaRx N.V. announced positive results from the European Phase II IXCHANGE study of a first-in-class anti-C5a antibody, vilobelimab, in patients with ANCA-associated vasculitis (AAV).

The Vasculitis Market is expected to grow at a strong CAGR of 3.5% during the forecast period owing to the rising technological advancements for treating vasculitis including advancements in genomic technologies. For instance, in July 2023, Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced that the first patient was treated with imlifidase in an investigator-initiated phase 2 study in anti-neutrophil cytoplasmic antibody-associated vasculitis. Several other factors such as increased investment in research, increasing adoption of biologics, rising per capita income, expanding healthcare expenditure, and improved patient outcomes are also leading to the surge in the market. For instance, according to the Centers for Medicare & Medicaid Services, U.S. healthcare expenditure grew 2.7% in 2021, reaching USD 12,914 per capita.

Based on drug type, the market is segmented into biologics, corticosteroids, and immunosuppressants. The corticosteroids segment held the highest share in the market in the year 2022 owing to its higher effectiveness and easy availability. Also, the consumption of corticosteroids like prednisone and methylprednisolone has risen over the years for treating vasculitis because of their fasting-acting property. For instance, in July 2020 to provide effective treatment for persons with ANCA-related vasculitis, ChemoCentryx, Inc., suggested US Food and Drug Administration (FDA) to submit a new drug application (NDA) for corticosteroids which will reduce the toxicity associated with daily steroid administration, resulting in better patient outcomes. Other factors such as the rise in the geriatric population are also strengthening grounds for the corticosteroids segment in the vasculitis market.

Based on disease type, the market is segmented into small vessel vasculitis, medium vessel vasculitis, and large vessel vasculitis. The small vessel vasculitis segment is expected to grow with the highest CAGR during the forecast period owing to rising cases of small blood vessel aneurysms globally. This growth has been supported by a surge in the usage of chemicals and pesticides. Also, rising geriatric population is driving the growth of this segment. For instance, according to the Administration for Community Living, 46.2 million people in the U.S. were above the age of 65 in 2014 and are estimated to reach 98 million in number by 2060. Thus, the rising cases of small vessel vasculitis are driving the growth of this modality.

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies category held the highest share in the market in 2022 attributed to the availability of all required medications at a place. Also, hospitals offer multiple reimbursement policies to ease the payment process for the ongoing medical treatment which facilitates the growth of this segment. Furthermore, rising number of hospitals and healthcare centers, the prevalence of vasculitis has been on the rise around the world, which has contributed to the growth of this segment globally. For instance, according to the American Hospital Association, there were about 6,100 hospitals in the U.S. in 2022, which comprised community hospitals run by non-profit organizations as well as state and local governments. Thus, the hospital pharmacies segment held dominance in the market in the year 2022.

For a better understanding of the market adoption of the vasculitis industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with the highest CAGR during the forecast period. Several factors, such as the rising prevalence of vasculitis, a large patient pool, a rising geriatric population, and rising research and development activities are driving the regional market growth. Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for vasculitis. In addition to this, rising obesity among adults is a major driving factor for this segment. For instance, the World Health Organization in 2021 estimated that in Southeast Asia 6.6 million young children under 5 years and one in five adults are currently overweight, which is expected to significantly rise in upcoming years. Hence, given the large population size of APAC, it is expected to grow with a high CAGR during the forecast period.

Some of the major players operating in the market include: AbbVie Inc.; Amgen Inc.; Amneal Pharmaceuticals, LLC.; F. Hoffmann-La Roche Ltd; GSK plc.; InflaRx GmbH; Novartis AG; Pfizer Inc.; Staidson Biopharma Inc.; Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Vasculitis Market
• 2.2. Research Methodology of the Vasculitis Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE VASCULITIS MARKET

6 VASCULITIS MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY DRUG TYPE

• 7.1. Biologics
• 7.2. Corticosteroids
• 7.3. Immunosuppressants

8 MARKET INSIGHTS BY DISEASE TYPE

• 8.1. Small Vessel Vasculitis
• 8.2. Medium Vessel Vasculitis
• 8.3. Large Vessel Vasculitis

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 VASCULITIS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges

12 VASCULITIS MARKET OPPORTUNITIES

13 VASCULITIS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. AbbVie Inc.
• 17.2. Amgen Inc.
• 17.3. Amneal Pharmaceuticals, LLC.
• 17.4. F. Hoffmann-La Roche Ltd
• 17.5. GSK plc.
• 17.6. InflaRx GmbH
• 17.7. Novartis AG
• 17.8. Pfizer Inc.
• 17.9. Staidson Biopharma Inc.
• 17.10. Teva Pharmaceutical Industries Ltd.

18 DISCLAIMER